Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

ConditionsMelanoma Stage III B-cell Non Hodgkin Lymphoma Pediatric ALL Childhood Non-Hodgkin Lymphoma Acute Lymphatic Leukemia Chronic Lymphatic Leukemia Melanoma Stage IV

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorMiltenyi Biomedicine GmbH

About this trial

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Eligibility criteria

Qualifiers

Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.

Patient has provided informed consent prior to enrollment.

Disqualifiers

No exclusion criteria

Trial design

Treatments tested in this trial

MB-CART19.1
MB-CART20.1
MB-CART2019.1

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

Charité Universitätsmedizin Berlin13353, Berlin Germany

Universitätsklinikum Köln50937, Cologne Germany

Uniklinikum Erlangen91054, Erlangen Germany

Universitätsmedizin Göttingen37075, Göttingen Germany

Sponsors and collaborators

Miltenyi Biomedicine GmbH

Lead sponsor

Source ClinicalTrials.gov